MEMGEN, INC.
5Patents
5Active
5Granted
43Portfolio score
Filing activity: Nov 2, 2016 → Nov 6, 2020
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11951141B2 | Replication-enhanced oncolytic adenoviruses | Chemistry; Metallurgy | 0 | Active |
| US12171803B2 | Methods of CD40 and toll like receptor immune activation | Chemistry; Metallurgy | 0 | Active |
| US11594135B2 | Methods of CD40 activation and immune checkpoint blockade | Electricity | 0 | Active |
| US12239666B2 | Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand | Chemistry; Metallurgy | 0 | Active |
| US11298420B2 | Armed oncolytic viruses | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.